Gain Therapeutics, Inc. (GANX) stock
GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.18+0.24 (+25.51%)
Close on Nov 17, 2026Market cap $51.50MP/E –Yield –
Gain Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Gain Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$18.95M. For fiscal 2025 it was -$18.47M. The highest annual figure on record is -$3.24M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$18.47M | – |
| FY2024 | Dec 31, 2024 | -$18.87M | – |
| FY2023 | Dec 31, 2023 | -$18.87M | – |
| FY2022 | Dec 31, 2022 | -$14.69M | – |
| FY2021 | Dec 31, 2021 | -$12.37M | – |
| FY2020 | Dec 31, 2020 | -$3.24M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.68M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.73M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.62M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.93M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.10M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.82M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.45M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.08M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.76M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.59M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.66M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.97M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.02M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.22M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.90M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.29M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.05M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.45M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.15M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.19M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.22M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.81M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.31M | – |
| Q3 FY2020 | Sep 30, 2020 | -$755.02K | – |
| Q2 FY2020 | Jun 30, 2020 | -$424.19K | – |
| Q1 FY2020 | Mar 31, 2020 | -$752.82K | – |
See a number that looks wrong?